-- Days : -- HRS : -- MIN : -- SEC

Register Now →

News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 1, 2024

IPF and PDE4B Inhibitors

Author(s)Steven D. Nathan, MD

Dr Nathan highlights the role of PDE4B inhibitors in IPF management.

Episodes in this series

Justin Oldham, MD, MS, an expert on IPF

EP. 1 Emerging Agents in IPF Treatment

Justin Oldham, MD, MS, an expert on IPF

EP. 2 IPF and PDE4B Inhibitors

Justin Oldham, MD, MS, an expert on IPF

EP. 3 Importance of Patient-Reported Outcomes

Justin Oldham, MD, MS, an expert on IPF

EP. 4 Future Possibilities in IPF Treatment

Justin Oldham, MD, MS, an expert on IPF

EP. 5 Advice for Clinicians Treating IPF

Justin Oldham, MD, MS, an expert on IPF

EP. 6 Current Standard of Care in IPF

Justin Oldham, MD, MS, an expert on IPF

EP. 7 Therapeutic Response and Disease Progression

Justin Oldham, MD, MS, an expert on IPF

EP. 8 Key Considerations for Selecting IPF Treatment

Justin Oldham, MD, MS, an expert on IPF

EP. 9 Economic Impact of IPF

Justin Oldham, MD, MS, an expert on IPF

EP. 10 Unmet Needs in IPF Landscape

Justin Oldham, MD, MS, an expert on IPF

EP. 11 Overview of Idiopathic Pulmonary Fibrosis (IPF)

Justin Oldham, MD, MS, an expert on IPF

EP. 12 Impact of IPF on Quality of Life and Financial Considerations

Justin Oldham, MD, MS, an expert on IPF

EP. 13 Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection

Justin Oldham, MD, MS, an expert on IPF

EP. 14 Clinical Presentation and Risk Factors

Justin Oldham, MD, MS, an expert on IPF

EP. 15 Impact of Comorbidities on IPF Management

Justin Oldham, MD, MS, an expert on IPF

EP. 16 Overcoming Treatment Barriers: Strategies for Success

Justin Oldham, MD, MS, an expert on IPF

EP. 17 Impact of Treatment Delays on Patient Outcomes

Video content above is prompted by the following:

What is the rationale for studying the phosphodiesterase 4 (PDE4) inhibitor pathway in idiopathic pulmonary fibrosis (IPF)?
How do PDE4 inhibitors differ from PDE4B inhibitors?
Why is this pathway of interest to pulmonologists and patients living with IPF?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Vitamin D3 | Image Credit: Adisak - stock.adobe.com

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

ByBrooke McCormick

August 6th 2026

Katherine Wilemon, CEO of the Family Heart Foundation

Almost No Public Awareness of Lp(a), Elevated CVD Risk in the US: Katherine Wilemon

ByPearl Steinzor,Katherine Wilemon

August 6th 2026

Eosinophilic esophagitis | Image Credit: syahrir - stock.adobe.com

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

ByBrooke McCormick

August 6th 2026

Experts featured in this series.

Translating PFS Data for Patients: How Community Oncologists Communicate Trial Outcomes in RRFL

ByRyan Haumschild, PharmD, MS, MBA, CPEL,Christina Poh, MD,Tara Graff DO, MS

August 6th 2026

Avoiding TNF Cycling: When to Switch Drug Classes in Rheumatoid Arthritis

ByJulia Buchfuhrer, DO

August 6th 2026

Trending on AJMC

FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success

Patients With MASLD Had More Than 2 Times Higher Odds of Eosinophilic Esophagitis Across Age Groups

Predicting GLP-1 Discontinuation From Pharmacy Claims

High-Dose Vitamin D3 Fails to Improve PFS in Phase 3 Metastatic CRC Trial

Full Data Published Showing 87% CR at 3 Years for Epcoritamab Plus BR in First-Line FL